ZYMEDI has a platform that fuels continuous innovation
Our in-house drug discovery platform is named HOMEOS, after ARSs’ capability of maintaining homeostasis. Also known as AIDD (aminoacyl-tRNA synthetase [ARS]-focused integrated drug development platform), it allows us to maintain a nonexhaustive pipeline of first-in-class drugs by exploring the plethora of ARS biology.
ARSs are associated with angiogenesis, inflammation, tumorigenesis, and other important pathophysiologic processes in human diseases. By targeting these pathways and their respective imbalances, we can help restore the body to balance.
We maintain a comprehensive proprietary database for all information related to ARS:
DARSOME: disease-associated ARS genome and proteome. In-depth analysis of proprietary disease-associated ARS variations (genome, proteome, and secretome database).
INTER-ARS: propriety ARS interactome database.
INTEGRA: integrated efficacy assay platform. The design of the disease-mimicking integrated drug-screening system.
MOST: multimodality lead discovery platform. Discovery of ARS-focused hits and leads (chemical, antibody, peptide, biologics).
AILO: AI-based lead optimization platform. Lead optimization for druggable candidates. First-in-class drug.